Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06606457 · ClinicalTrials.gov registry record · NA
PACE CF, a 3-session Mind-body Pain Management Program for Adults With Cystic Fibrosis
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT06606457: Completed NA study, sponsored by Massachusetts General Hospital.
NCT06606457 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06606457, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes unrecognized and under-managed in people with CF. Both medication and non-medication interventions can be used to treat pain and ideally, there is a multicomponent management approach. The goal of this study is to pilot a new 3-session non-medication mind-body pain management intervention specifically designed for adults with cystic fibrosis (CF). The intervention is titled Pain Acknowledgement Coping and Empowerment in CF (PACE CF). PACE CF will be administered by a member of the CF care team via telehealth visits to participants at home or during a hospitalization. The aim of the study is to evaluate the feasibility and patient acceptability of the intervention as well as preliminary evidence of the impact of the intervention on pain and its interference in daily life. The study will also examine outcomes such as perceived coping, quality of life, symptoms of depression or anxiety, and use of prescribed pain medication, in an exploratory manner.
Interventions
- BEHAVIORAL Pain Acknowledgment Coping and Empowerment in CF (PACE CF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2025-04-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06606457
The ClinicalTrials.gov registry entry for NCT06606457 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pain Acknowledgment Coping and Empowerment in CF (PACE CF) is the first listed.
NCT06606457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06606457 about?
NCT06606457 is a clinical study titled "PACE CF, a 3-session Mind-body Pain Management Program for Adults With Cystic Fibrosis". Many people living with cystic fibrosis (CF) experience pain. However, pain is sometimes unrecognized and under-managed in people with CF. Both medication and non-medication interventions can be used to treat pain and ideally, there is a multicomponent management approach. The goal of this study is...
What is the current status of trial NCT06606457?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2024-09-10. Estimated completion is 2025-04-09.
What interventions are being tested in trial NCT06606457?
The interventions under investigation include: Pain Acknowledgment Coping and Empowerment in CF (PACE CF) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06606457?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.